Novo Nordisk: Novo Nordisk expands presence in India and leverages artificial intelligence for growth

Copyright © BusinessAMBE 2023 Key takeaways Novo Nordisk plans to double the number of process managers in India over the next three to four years and expand its total workforce by 16 percent to 5,000 employees. The company is partnering with local AI start-ups to deploy AI for various tasks, including summarizing documents, extracting insights and detecting editing errors. Novo Nordisk's Indian center will become a virtual mirror image of its headquarters in Denmark within three years, particularly in terms of processing data critical to research and development. Novo Nordisk is significantly expanding its presence in India , driven by growing demand for its Wegovy weight-loss drug and the potential of artificial intelligence (AI). The company plans to double the number of global process leaders in India over the next three to four years and expand its total workforce by 16 percent to 5,000 employees next year. This expansion builds on Novo Nordisk's existing center in Bengaluru, which has been operational for 17 years and plays a crucial role in managing vast amounts of data related to drug safety and efficacy. This reports the Reuters news agency. A key focus of this expansion is collaboration with local AI start-ups. Novo Nordisk is currently working with 10 such companies to deploy AI for various tasks. These AI tools are already being implemented in the company's global operations, streamlining processes such as quality control of medical documents. Benefits of AI integration The use of AI has significantly reduced the time required for quality checks of documents intended for regulatory submissions in countries around the world. John Dawber , director of global business services at Novo Nordisk , highlighted this improvement by stating that thanks to AI, the process has been reduced from 40 hours per document to about 40 minutes. Dawber sees the Indian center becoming a virtual mirror image of the headquarters in Denmark within three years, especially in terms of processing data critical to research and development. While acknowledging the importance of collaboration between locations, he emphasizes the growing responsibility entrusted to the Bengaluru center for both current and future product development. Competition and market trends Novo Nordisk is not alone in making strategic investments in India . Other major pharmaceutical companies, such as Sanofi and Bristol Myers Squibb , are also making significant commitments to expand their operations in the country, driven by factors such as a skilled workforce and access to advanced technologies such as AI. Novo Nordisk's Indian office currently handles half of the company's global safety assessments, tracking and sharing reports on adverse drug reactions with health authorities worldwide. The Indian team also contributes to the production of various documents during the drug development process, including safety reports, brochure updates, risk management plans and other publications. Future plans and partnerships While specific investment amounts in the expansion of the Indian center and AI partnerships have not been disclosed, Novo Nordisk has confirmed it is open to collaborating with other AI startups in India . If you want access to all articles, enjoy our promo temporarily and subscribe here! © The Content Exchange, source News